Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06749457 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
A Phase 1 study of Staphylococcus Aureus, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT06749457 is a Phase 1 study of Staphylococcus Aureus that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 231 participants, below the 3,875-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06749457, a Phase 1 study of Staphylococcus Aureus, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD7760
Study Locations (20)
California
- Research Site - Chula Vista
- Research Site - Chula Vista
- Research Site - Glendale
- Research Site - Granada Hills
- Research Site - Los Angeles
- Research Site - Northridge
- Research Site - Northridge
- Research Site - Oxnard
- Research Site - Riverside
- Research Site - San Dimas
- Research Site - Tarzana
- Research Site - Valencia
- Research Site - Victorville
Florida
- Research Site - Bradenton
- Research Site - Coral Springs
- Research Site - Hollywood
- Research Site - Orlando
- Research Site - Tampa
Alabama
- Research Site - Huntsville
Colorado
- Research Site - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2027-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06749457
The ClinicalTrials.gov registry entry for NCT06749457 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,875-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (94% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Staphylococcus Aureus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06749457 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06749457 about?
NCT06749457 is a clinical study titled "A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)". The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
What is the current status of trial NCT06749457?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 231 participants. The study started on 2024-12-30. Estimated completion is 2027-07-06.
What conditions does trial NCT06749457 study?
This clinical trial studies the following conditions: Staphylococcus Aureus.
What interventions are being tested in trial NCT06749457?
The interventions under investigation include: Placebo (OTHER), AZD7760 (DRUG).
Who is sponsoring clinical trial NCT06749457?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06749457 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Staphylococcus Aureus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome
RECRUITING · Phase 1
-
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
COMPLETED · Phase 1
-
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
RECRUITING · Phase 4
-
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
COMPLETED
-
A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.